

Referenser - Take-home Naloxone

Take-home naloxone: a life saver in opioid overdose. *Lancet* 2019, 393(10169), 296.

Acharya, M., Chopra, D., Hayes, C. J., Teeter, B., & Martin, B. C. (2020). Cost-Effectiveness of Intranasal Naloxone Distribution to High-Risk Prescription Opioid Users. *Value Health, 23*(4), 451-460.

Ahamad, K., Dong, H., Johnson, C., Hyashi, K., DeBeck, K., Milloy, M. J., & Wood, E. (2019). Factors associated with willingness to wear an electronic overdose detection device. *Addict Sci Clin Pract, 14*(1), 23.

Alho, H., Dematteis, M., Lembo, D., Maremmani, I., Roncero, C., & Somaini, L. (2020). Opioid-related deaths in Europe: Strategies for a comprehensive approach to address a major public health concern. *Int J Drug Policy, 76*, 102616.

Allen, S. T., Grieb, S. M., O'Rourke, A., Yoder, R., Planchet, E., White, R. H., & Sherman, S. G. (2019). Understanding the public health consequences of suspending a rural syringe services program: a qualitative study of the experiences of people who inject drugs. *Harm Reduct J, 16*(1), 33.

A, M. O., & Buchman, D. Z. (2017). Commentary on McAuley et al. (2017): Naloxone programs must reduce marginalization and improve access to comprehensive emergency care. *Addiction, 112*(2), 309-310.

Ashrafioun, L., Gamble, S., Herrmann, M., & Baciewicz, G. (2016). Evaluation of knowledge and confidence following opioid overdose prevention training: A comparison of types of training participants and naloxone administration methods. *Subst Abus, 37*(1), 76-81.

Ashburn, N. P., Ryder, C. W., Angi, R. M., Snaveley, A. C., Nelson, R. D., Bozeman, W. P., . . . Stopyra, J. P. (2020). One-Year Mortality and Associated Factors in Patients Receiving Out-of-Hospital Naloxone for Presumed Opioid Overdose. *Ann Emerg Med, 75*(5), 559-567.

Ashton, H., & Hassan, Z. (2006). Best evidence topic report. Intranasal naloxone in suspected opioid overdose. *Emerg Med J, 23*(3), 221-223.

B.B., L., E.L, S., Rehav, M., Phelan, J. C., & Nuttbrock, L. (1997). On stigma and its consequences: evidence from a longitudinal study of men with dual diagnoses of mental illness and substance abuse. *J. Health Soc. Behav, 38*, 177-190.

Baca, C. T., & Grant, K. J. (2007). What heroin users tell us about overdose. *J Addict Dis, 26*(4), 63-68.

Bagley, S. M., Larochele, M. R., Xuan, Z., Wang, N., Patel, A., Bernson, D., . . . Walley, A. Y. (2020). Characteristics and Receipt of Medication Treatment Among Young Adults Who Experience a Nonfatal Opioid-Related Overdose. *Ann Emerg Med, 75*(1), 29-38.

Bagley, S. M., Forman, L. S., Ruiz, S., Cranston, K., & Walley, A. Y. (2018). Expanding access to naloxone for family members: The Massachusetts experience. *Drug Alcohol Rev, 37*(4), 480-486.

Bagley, S. M., Schoenberger, S. F., Waye, K. M., & Walley, A. Y. (2019). A scoping review of post opioid-overdose interventions. *Prev Med, 128*, 105813

Bailey, A. M., & Wermeling, D. P. (2014). Naloxone for opioid overdose prevention: pharmacists' role in community-based practice settings. *Ann Pharmacother, 48*(5), 601-606.

Balster, R. L., & Walsh, S. L. (2016). Ensure global access to naloxone for opioid overdose management. *Addiction, 111*(4), 589-590.

Banjo, O., Tzemis, D., Al-Qutub, D., Amlani, A., Kesselring, S., & Buxton, J. A. (2014). A quantitative and qualitative evaluation of the British Columbia Take Home Naloxone program. *CMAJ Open, 2*(3), E153-161.

Bardwell, G., Kerr, T., Boyd, J., & McNeil, R. (2018). Characterizing peer roles in an overdose crisis: Preferences for peer workers in overdose response programs in emergency shelters. *Drug Alcohol Depend, 190*, 6-8.

- Barry, T., Klimas, J., Tobin, H., Egan, M., & Bury, G. (2017). Opiate addiction and overdose: experiences, attitudes, and appetite for community naloxone provision. *Br J Gen Pract*, *67*(657), e267-e273.
- Barton, E. D., Colwell, C. B., Wolfe, T., Fosnocht, D., Gravitz, C., Bryan, T., . . . Bailey, J. (2005). Efficacy of intranasal naloxone as a needleless alternative for treatment of opioid overdose in the prehospital setting. *J Emerg Med*, *29*(3), 265-271.
- Barton, E. D., Ramos, J., Colwell, C., Benson, J., Baily, J., & Dunn, W. (2002). Intranasal administration of naloxone by paramedics. *Prehosp Emerg Care*, *6*(1), 54-58.
- Bagley, S. M., Schoenberger, S. F., Waye, K. M., & Walley, A. Y. (2019). A scoping review of post opioid-overdose interventions. *Prev Med*, *128*, 105813
- Beamish, L., Sagorin, Z., Stanley, C., English, K., Garelnabi, R., Cousineau, D., . . . Klimas, J. (2019). Implementation of a regional quality improvement collaborative to improve care of people living with opioid use disorder in a Canadian setting. *BMC Health Serv Res*, *19*(1), 663.
- Behar, E., Bagnulo, R., & Coffin, P. O. (2018). Acceptability and feasibility of naloxone prescribing in primary care settings: A systematic review. *Prev Med*, *114*, 79-87.
- Behar, E., Chang, J. S., Countess, K., Matheson, T., Santos, G. M., & Coffin, P. (2019). Perceived Causes of Personal versus Witnessed Overdoses among People who Inject Opioids. *Subst Use Misuse*, *54*(12), 1929-1937.
- Behar, E., Santos, G. M., Wheeler, E., Rowe, C., & Coffin, P. O. (2015). Brief overdose education is sufficient for naloxone distribution to opioid users. *Drug Alcohol Depend*, *148*, 209-212.
- Behar, E., Rowe, C., Santos, G. M., Murphy, S., & Coffin, P. O. (2016). Primary Care Patient Experience with Naloxone Prescription. *Ann Fam Med*, *14*(5), 431-436
- Bell, A., Bennett, A. S., Jones, T. S., Doe-Simkins, M., & Williams, L. D. (2019). Amount of naloxone used to reverse opioid overdoses outside of medical practice in a city with increasing illicitly manufactured fentanyl in illicit drug supply. *Subst Abuse*, *40*(1), 52-55.
- Bell, J., & Strang, J. (2020). Medication Treatment of Opioid Use Disorder. *Biol Psychiatry*, *87*(1), 82-88.
- Bennett, A. S., Bell, A., Doe-Simkins, M., Elliott, L., Pouget, E., & Davis, C. (2018). From Peers to Lay Bystanders: Findings from a Decade of Naloxone Distribution in Pittsburgh, PA. *J Psychoactive Drugs*, *50*(3), 240-246.
- Bessen, S., Metcalf, S. A., Saunders, E. C., Moore, S. K., Meier, A., McLeman, B., . . . Marsch, L. A. (2019). Barriers to naloxone use and acceptance among opioid users, first responders, and emergency department providers in New Hampshire, USA. *Int J Drug Policy*, *74*, 144-151.
- Best, D., Man, L. H., Gossop, M., Noble, A., & Strang, J. (2000). Drug users' experiences of witnessing overdoses: what do they know and what do they need to know? *Drug Alcohol Rev*, *19*(4), 407-412.
- Bird, S. M., McAuley, A., Munro, A., Hutchinson, S. J., & Taylor, A. (2017). Prison-based prescriptions aid Scotland's National Naloxone Programme. *Lancet*, *389*(10073), 1005-1006.
- Bird, S. M., McAuley, A., Perry, S., & Hunter, C. (2016). Effectiveness of Scotland's National Naloxone Programme for reducing opioid-related deaths: a before (2006-10) versus after (2011-13) comparison. *Addiction*, *111*(5), 883-891.
- Bird, S. M., Parmar, M. K., & Strang, J. (2015). Take-home naloxone to prevent fatalities from opiate-overdose: Protocol for Scotland's public health policy evaluation, and a new measure to assess impact. *Drugs (Abingdon Engl)*, *22*(1), 66-76.
- Bird, S. M., Strang, J., Ashby, D., Podmore, J., Robertson, J. R., Welch, S., . . . Parmar, M. K. B. (2017). External data required timely response by the Trial Steering-Data Monitoring Committee for the NALoxone InVEstigation (N-ALIVE) pilot trial. *Contemp Clin Trials Commun*, *5*, 100-106.

- Black, L., Connolly, I., Getty, M., Hogan, C., Lennon, P., Mc Cusker, M., . . . Strang, J. (2017). Poor implementation of naloxone needs to be better understood in order to save lives. *Addiction, 112*(5), 911-912.
- Boeri, M., & Lamonica, A. K. (2020). Naloxone perspectives from people who use opioids: Findings from an ethnographic study in three states. *J Am Assoc Nurse Pract.*
- Bohnert, A. S., Tracy, M., & Galea, S. (2009). Circumstances and witness characteristics associated with overdose fatality. *Ann Emerg Med, 54*(4), 618-624.
- Bohnert, A. S., Tracy, M., & Galea, S. (2012). Characteristics of drug users who witness many overdoses: implications for overdose prevention. *Drug Alcohol Depend, 120*(1-3), 168-173.
- Bolshakova, M., Bluthenthal, R., & Sussman, S. (2019). Opioid use and misuse: health impact, prevalence, correlates and interventions. *Psychol Health, 34*(9), 1105-1139.
- Bounthavong, M., Suh, K., Christopher, M. L. D., Veenstra, D. L., Basu, A., & Devine, E. B. (2019). Providers' perceptions on barriers and facilitators to prescribing naloxone for patients at risk for opioid overdose after implementation of a national academic detailing program: A qualitative assessment. *Res Social Adm Pharm.*
- Bowles, J. M., & Lankenau, S. E. (2019). "I Gotta Go With Modern Technology, So I'm Gonna Give 'em the Narcan": The Diffusion of Innovations and an Opioid Overdose Prevention Program. *Qual Health Res, 29*(3), 345-356.
- Bowles, J. M., Smith, L. R., Verdugo, S. R., Wagner, K. D., & Davidson, P. J. (2020). "Generally, you get 86'ed because you're a liability": An application of Integrated Threat Theory to frequently witnessed overdoses and social distancing responses. *Soc Sci Med, 260*, 113190.
- Boyer, E. W. (2012). Management of opioid analgesic overdose. *N Engl J Med, 367*(2), 146-155.
- Brady, J. E., DiMaggio, C. J., Keyes, K. M., Doyle, J. J., Richardson, L. D., & Li, G. (2015). Emergency department utilization and subsequent prescription drug overdose death. *Ann Epidemiol, 25*(8), 613-619.e612.
- Buresh, M., Gicquelais, R. E., Astemborski, J., Kirk, G. D., Mehta, S. H., & Genberg, B. L. (2020). Fatal overdose prevention and experience with naloxone: A cross-sectional study from a community-based cohort of people who inject drugs in Baltimore, Maryland. *PLoS One, 15*(3), e0230127.
- Caudarella, A., Dong, H., Milloy, M. J., Kerr, T., Wood, E., & Hayashi, K. (2016). Non-fatal overdose as a risk factor for subsequent fatal overdose among people who inject drugs. *Drug Alcohol Depend, 162*, 51-55.
- Campbell, N. D. (2019). Naloxone as a technology of solidarity: history of opioid overdose prevention. *Cmaj, 191*(34), E945-e946.
- Campbell, G., Nielsen, S., Bruno, R., Lintzeris, N., Cohen, M., Hall, W., . . . Degenhardt, L. (2015). The Pain and Opioids IN Treatment study: characteristics of a cohort using opioids to manage chronic non-cancer pain. *Pain, 156*(2), 231-242.
- Chang, H. Y., Krawczyk, N., Schneider, K. E., Ferris, L., Eisenberg, M., Richards, T. M., . . . Saloner, B. (2019). A predictive risk model for nonfatal opioid overdose in a statewide population of buprenorphine patients. *Drug Alcohol Depend, 201*, 127-133.
- Chang, K. C., Wang, J. D., Saxon, A., Matthews, A. G., Woody, G., & Hser, Y. I. (2017). Causes of death and expected years of life lost among treated opioid-dependent individuals in the United States and Taiwan. *Int J Drug Policy, 43*, 1-6.
- Chen, Y., Wang, Y., Nielsen, S., Kuhn, L., & Lam, T. (2020). A systematic review of opioid overdose interventions delivered within emergency departments. *Drug Alcohol Depend, 213*, 108009.
- Chichester, K., Sisson, M. L., Schiavon, S. P., Hugley, M. J., Hendricks, P. S., Shelton, R. C., & Cropsey, K. L. (2020). Naloxone Training From Nonmedical Personnel: Benefits Before, During, and After Overdose Events. *J Addict Med.*
- Chou, R., Dana, T., Blazina, I., Grusing, S., Fu, R., & Bougatsos, C. (2020). U.S. Preventive Services Task Force Evidence

Syntheses, formerly Systematic Evidence Reviews *Interventions for Unhealthy Drug Use—Supplemental Report: A Systematic Review for the U.S. Preventive Services Task Force*. Rockville (MD): Agency for Healthcare Research and Quality (US).

Chou, R., Korthuis, P. T., McCarty, D., Coffin, P. O., Griffin, J. C., Davis-O'Reilly, C., . . . Daya, M. (2017). Management of Suspected Opioid Overdose With Naloxone in Out-of-Hospital Settings: A Systematic Review. *Ann Intern Med*, *167*(12), 867-875.

Ciccarone, D. (2019). The triple wave epidemic: Supply and demand drivers of the US opioid overdose crisis. *Int J Drug Policy*, *71*, 183-188.

Clark, A. K., Wilder, C. M., & Winstanley, E. L. (2014). A systematic review of community opioid overdose prevention and naloxone distribution programs. *J Addict Med*, *8*(3), 153-163.

Clarke, S. F., Dargan, P. I., & Jones, A. L. (2005). Naloxone in opioid poisoning: walking the tightrope. *Emerg Med J*, *22*(9), 612-616.

Coe, M. A., & Walsh, S. L. (2015). Distribution of naloxone for overdose prevention to chronic pain patients. *Prev Med*, *80*, 41-43.

Cohen, B. R., Mahoney, K. M., Baro, E., Squire, C., Beck, M., Travis, S., . . . Woodcock, J. (2020). FDA Initiative for Drug Facts Label for Over-the-Counter Naloxone. *N Engl J Med*, *382*(22), 2129-2136.

Coffin, P. O., & Sullivan, S. D. (2013). Cost-effectiveness of distributing naloxone to heroin users for lay overdose reversal. *Ann Intern Med*, *158*(1), 1-9.

Coffin, P. O., Behar, E., Rowe, C., Santos, G. M., Coffa, D., Bald, M., & Vittinghoff, E. (2016). Nonrandomized Intervention Study of Naloxone Coprescription for Primary Care Patients Receiving Long-Term Opioid Therapy for Pain. *Ann Intern Med*, *165*(4), 245-25

Colledge, S., Peacock, A., Leung, J., Larney, S., Grebely, J., Hickman, M., . . . Degenhardt, L. (2019). The prevalence of non-fatal overdose among people who inject drugs: A multi-stage systematic review and meta-analysis. *Int J Drug Policy*, *73*, 172-184.

Corrigan, M., Wilson, S. S., & Hampton, J. (2015). Safety and efficacy of intranasally administered medications in the emergency department and prehospital settings. *Am J Health Syst Pharm*, *72*(18), 1544-1554.

Crabtree, A., & Masuda, J. R. (2019). Naloxone urban legends and the opioid crisis: what is the role of public health? *BMC Public Health*, *19*(1), 670.

Darke, S. (2016). Heroin overdose. *Addiction*, *111*(11), 2060-2063.

Darke, S., & Duflo, J. (2016). The toxicology of heroin-related death: estimating survival times. *Addiction*, *111*(9), 1607-1613.

Darke, S., & Hall, W. (1997). The distribution of naloxone to heroin users. *Addiction*, *92*(9), 1195-1199.

Darke, S., Mattick, R. P., & Degenhardt, L. (2003). The ratio of non-fatal to fatal heroin overdose. *Addiction*, *98*(8), 1169-1171.

Darke, S., Williamson, A., Ross, J., Mills, K. L., Havard, A., & Teesson, M. (2007). Patterns of nonfatal heroin overdose over a 3-year period: findings from the Australian treatment outcome study. *J Urban Health*, *84*(2), 283-291.

Davis, C. S. (2019). Commentary on Neale et al. (2019): Foregrounding the competency, expertise and rights of people who use drugs. *Addiction*, *114*(4), 719-720.

Dayton, L., Gicquelais, R. E., Tobin, K., Davey-Rothwell, M., Falade-Nwulia, O., Kong, X., . . . Latkin, C. (2019). More than just availability: Who has access and who administers take-home naloxone in Baltimore, MD. *PLoS One*, *14*(11), e0224686.

Degenhardt, L., Grebely, J., Stone, J., Hickman, M., Vickerman, P., Marshall, B. D. L., . . . Larney, S. (2019). Global patterns of opioid use and dependence: harms to populations, interventions, and future action. *Lancet*, *394*(10208), 1560-1579.

Degenhardt, L., Hall, W., & Adelstein, B. A. (2001). Ambulance calls to suspected overdoses: New South Wales patterns July 1997 to June 1999. *Aust N Z J Public Health*, *25*(5), 447-450.

Degenhardt, L., Randall, D., Hall, W., Law, M., Butler, T., & Burns, L. (2009). Mortality among clients of a state-wide opioid pharmacotherapy program over 20 years: risk factors and lives saved. *Drug Alcohol Depend*, *105*(1-2), 9-15.

Dettmer, K., Saunders, B., & Strang, J. (2001). Take home naloxone and the prevention of deaths from opiate overdose: two pilot schemes. *BMJ*, *322*(7291), 895-896.

Dietze, P. M., Draper, B., Olsen, A., Chronister, K. J., van Beek, I., Lintzeris, N., . . . Lenton, S. (2018). Does training people to administer take-home naloxone increase their knowledge? Evidence from Australian programs. *Drug Alcohol Rev*, *37*(4), 472-479.

Dietze, P., Jauncey, M., Salmon, A., Mohebbi, M., Latimer, J., van Beek, I., . . . Kerr, D. (2019). Effect of Intranasal vs Intramuscular Naloxone on Opioid Overdose: A Randomized Clinical Trial. *JAMA Netw Open*, *2*(11), e1914977.

Dietze, P. M., Stare, M., Cogger, S., Nambiar, D., Olsen, A., Burns, L., & Lenton, S. (2018). Knowledge of naloxone and take-home naloxone programs among a sample of people who inject drugs in Australia: Variations across capital cities. *Drug Alcohol Rev*, *37*(4), 457-463.

Doe-Simkins, M., Quinn, E., Xuan, Z., Sorensen-Alawad, A., Hackman, H., Ozonoff, A., & Walley, A. Y. (2014). Overdose rescues by trained and untrained participants and change in opioid use among substance-using participants in overdose education and naloxone distribution programs: a retrospective cohort study. *BMC Public Health*, *14*, 297.

Doe-Simkins, M., Walley, A. Y., Epstein, A., & Moyer, P. (2009). Saved by the nose: bystander-administered intranasal naloxone hydrochloride for opioid overdose. *Am J Public Health*, *99*(5), 788-791.

Donaghy, J. (2019). Opioid users reflect on their experiences responding to suspected opioid overdoses using take-home naloxone. *Evid Based Nurs*, *22*(3), 77.

Dowell, D., Noonan, R. K., & Houry, D. (2017). Underlying Factors in Drug Overdose Deaths. *Jama*, *318*(23), 2295-2296.

Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain – United States, 2016. *MMWR Recomm Rep* 2016; *65*:1–49

Doyon, S., Aks, S. E., & Schaeffer, S. (2014). Expanding access to naloxone in the United States. *J Med Toxicol*, *10*(4), 431-434.

Drainoni, M. L., Koppelman, E. A., Feldman, J. A., Walley, A. Y., Mitchell, P. M., Ellison, J., & Bernstein, E. (2016). Why is it so hard to implement change? A qualitative examination of barriers and facilitators to distribution of naloxone for overdose prevention in a safety net environment. *BMC Res Notes*, *9*(1), 465.

Dunne, R. B. (2018). Prescribing naloxone for opioid overdose intervention. *Pain Manag*, *8*(3), 197-208.

Dwyer, K., Walley, A. Y., Langlois, B. K., Mitchell, P. M., Nelson, K. P., Cromwell, J., & Bernstein, E. (2015). Opioid education and nasal naloxone rescue kits in the emergency department. *West J Emerg Med*, *16*(3), 381-384.

Dwyer, K., Walley, A. Y., Langlois, B. K., Mitchell, P. M., Nelson, K. P., Cromwell, J., & Bernstein, E. (2015). Opioid education and nasal naloxone rescue kits in the emergency department. *West J Emerg Med*, *16*(3), 381-384.

Dwyer, K., Walley, A. Y., Langlois, B. K., Mitchell, P. M., Nelson, K. P., Cromwell, J., & Bernstein, E. (2015). Opioid education and nasal naloxone rescue kits in the emergency department. *West J Emerg Med*, *16*(3), 381-384.

Dwyer, R., Olsen, A., Fowlie, C., Gough, C., van Beek, I., Jauncey, M., . . . Lenton, S. (2018). An overview of take-home naloxone programs in Australia. *Drug Alcohol Rev*, 37(4), 440-449.

Dwyer R., Fraser S., and Dietze P. (2016) Benefits and barriers to expanding the availability of take-home naloxone in Australia: A quantitative study. *Drugs: Education, Prevention and Policy*, 23, 388-396.

Dydyk, A. M., Jain, N. K., & Gupta, M. (2020). Opioid Use Disorder *StatPearls*. Treasure Island (FL): StatPearls Publishing

Copyright © 2020, StatPearls Publishing LLC.

Eggleston, W., Calleo, V., Kim, M., & Wojcik, S. (2020). Naloxone Administration by Untrained Community Members. *Pharmacotherapy*, 40(1), 84-88

Eswaran, V., Allen, K. C., Cruz, D. S., Lank, P. M., McCarthy, D. M., & Kim, H. S. (2020). Development of a take-home naloxone program at an urban academic emergency department. *J Am Pharm Assoc* (2003).

Evans, J. L., Tsui, J. I., Hahn, J. A., Davidson, P. J., Lum, P. J., & Page, K. (2012). Mortality among young injection drug users in San Francisco: a 10-year follow-up of the UFO study. *Am J Epidemiol*, 175(4), 302-308.

Eswaran, V., Allen, K. C., Bottari, D. C., Splawski, J. A., Bains, S., Aks, S. E., . . . Kim, H. S. (2020). Take-Home Naloxone Program Implementation: Lessons Learned From Seven Chicago-Area Hospitals. *Ann Emerg Med*, 76(3), 318-327.

Fairbairn, N., Coffin, P. O., & Walley, A. Y. (2017). Naloxone for heroin, prescription opioid, and illicitly made fentanyl overdoses: Challenges and innovations responding to a dynamic epidemic. *Int J Drug Policy*, 46, 172-179.

Faulkner-Gurstein, R. (2017). The social logic of naloxone: Peer administration, harm reduction, and the transformation of social policy. *Soc Sci Med*, 180, 20-27.

Farrugia, A., Fraser, S., Dwyer, R., Fomiatti, R., Neale, J., Dietze, P., & Strang, J. (2019). Take-home naloxone and the politics of care. *Sociol Health Illn*, 41(2), 427-443.

Farrugia, A. (2019). Commentary on Elliott et al. (2019): How stigma shapes overdose revival and possible avenues to disrupt it. *Addiction*, 114(8), 1387-1388.

Feuerstein-Simon, R., Lowenstein, M., Sharma, M., Dupuis, R., Luna Marti, X., & Cannuscio, C. C. (2020). Local health departments and the implementation of evidence-based policies to address opioid overdose mortality. *Subst Abus*, 1-7.

Fidacaro, G. A., Jr., Patel, P., Carroll, G., Bartimus, H., Hunter, K., & Hong, R. (2020). Do Patients Require Emergency Department Interventions After Prehospital Naloxone? *J Addict Med*, 14(3), 224-230.

Fomiatti, R., Farrugia, A., Fraser, S., Dwyer, R., Neale, J., & Strang, J. (2020). Addiction stigma and the production of impediments to take-home naloxone uptake. *Health (London)*, 1363459320925863.

Frank, D., Mateu-Gelabert, P., Guarino, H., Bennett, A., Wendel, T., Jessell, L., & Teper, A. (2015). High risk and little knowledge: overdose experiences and knowledge among young adult nonmedical prescription opioid users. *Int J Drug Policy*, 26(1), 84-91.

Frank, C. J., Kushner, S. E., Doran, D. A., & Stehr-Green, J. (2018). Mandatory Reporting of Fatal and Nonfatal Opioid Overdoses in a Rural Public Health Department. *Am J Public Health*, 108(12), 1646-1648.

Fraser, S., Farrugia, A., & Dwyer, R. (2018). Grievable lives? Death by opioid overdose in Australian newspaper coverage. *Int J Drug Policy*, 59, 28-35.

Gicquelais, R. E., Bohnert, A. S. B., & Fernandez, A. C. (2020). Opportunities to boost naloxone awareness among people who misuse opioid analgesics who have not used illegal opioids. *Subst Abus*, 1-5.

Gisev, N., Pearson, S. A., Dobbins, T., Currow, D. C., Blyth, F., Larney, S., . . . Degenhardt, L. (2018). Combating escalating harms associated with pharmaceutical opioid use in Australia: the POPPY II study protocol. *BMJ Open*,

8(12), e025840

Glaser, A., Arakaki, D., Chan, G. M., & Hoffman, R. S. (2005). Randomised trial of intranasal versus intramuscular naloxone in prehospital treatment for suspected opioid overdose. *Med J Aust*, 182(8), 427; author reply 427, 429.

Goldman-Hasbun, J., DeBeck, K., Buxton, J. A., Nosova, E., Wood, E., & Kerr, T. (2017). Knowledge and possession of take-home naloxone kits among street-involved youth in a Canadian setting: a cohort study. *Harm Reduct J*, 14(1), 79.

Goldman, J. E., Wayne, K. M., Periera, K. A., Krieger, M. S., Yedinak, J. L., & Marshall, B. D. L. (2019). Perspectives on rapid fentanyl test strips as a harm reduction practice among young adults who use drugs: a qualitative study. *Harm Reduct J*, 16(1), 3.

Greene, J. A., Deveau, B. J., Dol, J. S., & Butler, M. B. (2019). Incidence of mortality due to rebound toxicity after 'treat and release' practices in prehospital opioid overdose care: a systematic review. *Emerg Med J*, 36(4), 219-224.

Green, T. C., Ray, M., Bowman, S. E., McKenzie, M., & Rich, J. D. (2014). Two cases of intranasal naloxone self-administration in opioid overdose. *Subst Abus*, 35(2), 129-132.

Green, T. C., Soipe, A., Baloy, B., Burstein, D., Xuan, Z., Tapper, A., . . . Baird, J. (2020). Pharmacy on-site overdose protocols and prevention of overdose. *Subst Abus*, 1-5.

Gruver, B. R., Jiroutek, M. R., & Kelly, K. E. (2020). Naloxone coprescription in U.S. ambulatory care centers and emergency departments. *J Am Pharm Assoc (2003)*

Gufford, B. T., Ainslie, G. R., White, J. R., Jr., Layton, M. E., Padowski, J. M., Pollack, G. M., & Paine, M. F. (2017). Comparison of a New Intranasal Naloxone Formulation to Intramuscular Naloxone: Results from Hypothesis-generating Small Clinical Studies. *Clin Transl Sci*, 10(5), 380-386.

Gunn, A. H., Smothers, Z. P. W., Schramm-Sapyta, N., Freiermuth, C. E., MacEachern, M., & Muzyk, A. J. (2018). The Emergency Department as an Opportunity for Naloxone Distribution. *West J Emerg Med*, 19(6), 1036-1042.

Hall, W., & Strang, J. (2017). Value for money in reducing opioid-related deaths. *Lancet Public Health*, 2(3), e124-e125.

Handanagic, S., Bozicevic, I., Sekerija, M., Rutherford, G. W., & Begovac, J. (2019). Overdose mortality rates in Croatia and factors associated with self-reported drug overdose among persons who inject drugs in three Croatian cities. *Int J Drug Policy*, 64, 95-102.

Hanson, B. L., Porter, R. R., Zöld, A. L., & Terhorst-Miller, H. (2020). Preventing opioid overdose with peer-administered naloxone: findings from a rural state. *Harm Reduct J*, 17(1), 4.

Heavey, S. C., Chang, Y. P., Vest, B. M., Collins, R. L., Wieczorek, W., & Homish, G. G. (2018). 'I have it just in case' - Naloxone access and changes in opioid use behaviours. *Int J Drug Policy*, 51, 27-35.

Horsburgh, K., & McAuley, A. (2018). Scotland's national naloxone program: The prison experience. *Drug Alcohol Rev*, 37(4), 454-456.

Horton, M., McDonald, R., Green, T. C., Nielsen, S., Strang, J., Degenhardt, L., & Larney, S. (2017). A mapping review of take-home naloxone for people released from correctional settings. *Int J Drug Policy*, 46, 7-16.

Hser, Y. I., Evans, E., Grella, C., Ling, W., & Anglin, D. (2015). Long-term course of opioid addiction. *Harv Rev Psychiatry*, 23(2), 76-89.

Hulenvik, P., Frank, A., Medvedeo, A., & Berglund, M. (2007). Self-reported and observed heroin overdoses in Malmoe AU - Brådvik, Louise. *Journal of Substance Use*, 12(2), 119-126.

Hurt, B. R., Hussain, A., Aledhaim, A., Moayed, S., Schenkel, S. M., & Kim, H. K. (2020). Access and Barriers to Take-Home Naloxone Use among Emergency Department Patients with Opioid Misuse in Baltimore, Maryland, USA.

Subst Use Misuse, 1-6.

Jennifer, A., Jennifer, S., & Sandro, G. (2007). Stigma, discrimination and the health of illicit drug users. *Drug Alcohol Depend*, 88, 188-196.

Jin, H., Marshall, B. D. L., Degenhardt, L., Strang, J., Hickman, M., Fiellin, D. A., . . . Larney, S. (2020). Global opioid agonist treatment: a review of clinical practices by country. *Addiction*.

Jones, J. D., Campbell, A., Metz, V. E., & Comer, S. D. (2017). No evidence of compensatory drug use risk behavior among heroin users after receiving take-home naloxone. *Addict Behav*, 71, 104-106.

Jones, J. D., Campbell, A. N., Brandt, L., Castillo, F., Abbott, R., & Comer, S. D. (2020). Intervention in an opioid overdose event increases interest in treatment among individuals with opioid use disorder. *Subst Abuse*, 1-5.

Jones, J. D., Roux, P., Stancliff, S., Matthews, W., & Comer, S. D. (2014). Brief overdose education can significantly increase accurate recognition of opioid overdose among heroin users. *International Journal of Drug Policy*, 25, 166-170.

Jones, M., Bell, F., Bengler, J., Black, S., Buykx, P., Dixon, S., . . . Snooks, H. (2020). Protocol for Take-home naloxone In Multicentre Emergency (TIME) settings: feasibility study. *Pilot Feasibility Stud*, 6, 96.

Jordan, M. R., & Morrisonponce, D. (2020). *Naloxone StatPearls*. Treasure Island (FL): StatPearls Publishing

Copyright © 2020, StatPearls Publishing LLC.

Jozaghi, E. (2020). The Opioid Epidemic: Task-Shifting in Health Care and the Case for Access to Harm Reduction for People Who Use Drugs. *Int J Health Serv*, 20731420914820.

Kahn, L. S., Wozniak, M., Vest, B. M., & Moore, C. (2020). "Narcan encounters:" overdose and naloxone rescue experiences among people who use opioids. *Subst Abuse*, 1-14.

Kano, M., Salvador, J. G., Katzman, W., Sussman, A. L., & Takeda, M. Y. (2020). "You've got to care to carry this stuff" Community implications from take-home naloxone use: A qualitative study. *J Subst Abuse Treat*, 115, 108030.

Karlsen, A. P., Pedersen, D. M., Trautner, S., Dahl, J. B., & Hansen, M. S. (2014). Safety of intranasal fentanyl in the out-of-hospital setting: a prospective observational study. *Ann Emerg Med*, 63(6), 699-703.

Katzman, J. G., Greenberg, N. H., Takeda, M. Y., & Moya Balasch, M. (2019). Characteristics of Patients With Opioid Use Disorder Associated With Performing Overdose Reversals in the Community: An Opioid Treatment Program Analysis. *J Addict Med*, 13(2), 131-138.

Katzman, J. G., Takeda, M. Y., Bhatt, S. R., Moya Balasch, M., Greenberg, N., & Yonas, H. (2018). An Innovative Model for Naloxone Use Within an OTP Setting: A Prospective Cohort Study. *J Addict Med*, 12(2), 113-118

Katzman, J. G., Takeda, M. Y., Greenberg, N., Moya Balasch, M., Alchbli, A., Katzman, W. G., . . . Bhatt, S. R. (2020). Association of Take-Home Naloxone and Opioid Overdose Reversals Performed by Patients in an Opioid Treatment Program. *JAMA Netw Open*, 3(2), e200117.

Kestler, A., Buxton, J., Meckling, G., Giesler, A., Lee, M., Fuller, K., . . . Scheuermeyer, F. (2017). Factors Associated With Participation in an Emergency Department-Based Take-Home Naloxone Program for At-Risk Opioid Users. *Ann Emerg Med*, 69(3), 340-346

Kelly, A. M., Kerr, D., Dietze, P., Patrick, I., Walker, T., & Koutsogiannis, Z. (2005). Randomised trial of intranasal versus intramuscular naloxone in prehospital treatment for suspected opioid overdose. *Med J Aust*, 182(1), 24-27.

Kelly, A. M., & Koutsogiannis, Z. (2002). Intranasal naloxone for life threatening opioid toxicity. *Emerg Med J*, 19(4), 375.

Kelty, E., & Hulse, G. (2017). Fatal and non-fatal opioid overdose in opioid dependent patients treated with methadone, buprenorphine or implant naltrexone. *Int J Drug Policy*, 46, 54-60.

- Kerensky, T., & Walley, A. Y. (2017). Opioid overdose prevention and naloxone rescue kits: what we know and what we don't know. *Addict Sci Clin Pract*, *12*(1), 4.
- Kerr, D., Dietze, P., & Kelly, A. M. (2008). Intranasal naloxone for the treatment of suspected heroin overdose. *Addiction*, *103*(3), 379-386.
- Kerr, D., Dietze, P., Kelly, A. M., & Jolley, D. (2008). Attitudes of Australian heroin users to peer distribution of naloxone for heroin overdose: perspectives on intranasal administration. *J Urban Health*, *85*(3), 352-360.
- Kerr, D., Kelly, A. M., Dietze, P., Jolley, D., & Barger, B. (2009). Randomized controlled trial comparing the effectiveness and safety of intranasal and intramuscular naloxone for the treatment of suspected heroin overdose. *Addiction*, *104*(12), 2067-2074.
- Khatiwoda, P., Proeschold-Bell, R. J., Meade, C. S., Park, L. P., & Proescholdbell, S. (2018). Facilitators and Barriers to Naloxone Kit Use Among Opioid-Dependent Patients Enrolled in Medication Assisted Therapy Clinics in North Carolina. *N C Med J*, *79*(3), 149-155.
- Kline, A., Mattern, D., Cooperman, N., Dooley-Budsock, P., Williams, J. M., & Borys, S. (2020). "A Blessing and a Curse:" Opioid Users' Perspectives on Naloxone and the Epidemic of Opioid Overdose. *Subst Use Misuse*, *55*(8), 1280-1287.
- Knowlton, A., Weir, B. W., Hazzard, F., Olsen, Y., McWilliams, J., Fields, J., & Gaasch, W. (2013). EMS runs for suspected opioid overdose: implications for surveillance and prevention. *Prehosp Emerg Care*, *17*(3), 317-329.
- Kirane, H., Ketteringham, M., Bereket, S., Dima, R., Basta, A., Mendoza, S., & Hansen, H. (2016). Awareness and Attitudes Toward Intranasal Naloxone Rescue for Opioid Overdose Prevention. *J Subst Abuse Treat*, *69*, 44-49.
- Kirane, H., Ketteringham, M., Bereket, S., Dima, R., Basta, A., Mendoza, S., & Hansen, H. (2016). Awareness and Attitudes Toward Intranasal Naloxone Rescue for Opioid Overdose Prevention. *J Subst Abuse Treat*, *69*, 44-49.
- Klimas, J., Egan, M., Tobin, H., Coleman, N., & Bury, G. (2015). Development and process evaluation of an educational intervention for overdose prevention and naloxone distribution by general practice trainees. *BMC Med Educ*, *15*, 206.
- Kolla, G., & Strike, C. (2019). 'It's too much, I'm getting really tired of it': Overdose response and structural vulnerabilities among harm reduction workers in community settings. *Int J Drug Policy*, *74*, 127-135.
- Kral, A. H., Lambdin, B. H., Wenger, L. D., & Davidson, P. J. (2020). Evaluation of an Unsanctioned Safe Consumption Site in the United States. *N Engl J Med*, *383*(6), 589-590.
- Krieter, P. A., Chiang, C. N., Gyaw, S., & McCann, D. J. (2019). Comparison of the Pharmacokinetic Properties of Naloxone Following the Use of FDA-Approved Intranasal and Intramuscular Devices Versus a Common Improvised Nasal Naloxone Device. *J Clin Pharmacol*, *59*(8), 1078-1084.
- Krieter, P., Chiang, N., Gyaw, S., Skolnick, P., Crystal, R., Keegan, F., . . . Harris, J. (2016). Pharmacokinetic Properties and Human Use Characteristics of an FDA-Approved Intranasal Naloxone Product for the Treatment of Opioid Overdose. *J Clin Pharmacol*, *56*(10), 1243-1253.
- Kunoe, N., Opheim, A., Solli, K. K., Gaulen, Z., Sharma-Haase, K., Latif, Z. E., & Tanum, L. (2016). Design of a randomized controlled trial of extended-release naltrexone versus daily buprenorphine-naloxone for opioid dependence in Norway (NTX-SBX). *BMC Pharmacol Toxicol*, *17*(1), 18.
- Lagu, T., Anderson, B. J., & Stein, M. (2006). Overdoses among friends: drug users are willing to administer naloxone to others. *J Subst Abuse Treat*, *30*(2), 129-133.
- Lambdin, B. H., Zibbell, J., Wheeler, E., & Kral, A. H. (2018). Identifying gaps in the implementation of naloxone programs for laypersons in the United States. *Int J Drug Policy*, *52*, 52-55.
- Langham, S., Wright, A., Kenworthy, J., Grieve, R., & Dunlop, W. C. N. (2018). Cost-Effectiveness of Take-Home

Naloxone for the Prevention of Overdose Fatalities among Heroin Users in the United Kingdom. *Value Health*, 21(4), 407-415.

Lambdin, B. H., Bluthenthal, R. N., Wenger, L. D., Wheeler, E., Garner, B., Lakosky, P., & Kral, A. H. (2020). Overdose Education and Naloxone Distribution Within Syringe Service Programs - United States, 2019. *MMWR Morb Mortal Wkly Rep*, 69(33), 1117-1121.

Lankenau, S. E., Wagner, K. D., Silva, K., Kecojevic, A., Iverson, E., McNeely, M., & Kral, A. H. (2013). Injection drug users trained by overdose prevention programs: responses to witnessed overdoses. *J Community Health*, 38(1), 133-141.

Latkin, C. A., Dayton, L., Davey-Rothwell, M. A., & Tobin, K. E. (2019). Fentanyl and Drug Overdose: Perceptions of Fentanyl Risk, Overdose Risk Behaviors, and Opportunities for Intervention among People who use Opioids in Baltimore, USA. *Subst Use Misuse*, 54(6), 998-1006.

Latkin, C. A., Gicquelais, R. E., Clyde, C., Dayton, L., Davey-Rothwell, M., German, D., . . . Tobin, K. (2019). Stigma and drug use settings as correlates of self-reported, non-fatal overdose among people who use drugs in Baltimore, Maryland. *Int J Drug Policy*, 68, 86-92.

Leece, P., Cavacuiti, C., Macdonald, E. M., Gomes, T., Kahan, M., Srivastava, A., . . . Juurlink, D. N. (2015). Predictors of Opioid-Related Death During Methadone Therapy. *J Subst Abuse Treat*, 57, 30-35.

Lenton, S. R., Dietze, P. M., Degenhardt, L., Darke, S., & Butler, T. G. (2009). Now is the time to take steps to allow peer access to naloxone for heroin overdose in Australia. *Drug Alcohol Rev*, 28(6), 583-585.

Lenton, S. R., Dietze, P. M., Degenhardt, L., Darke, S., & Butler, T. G. (2009). Naloxone for administration by peers in cases of heroin overdose. *Med J Aust*, 191(8), 469.

Lenton, S., Dietze, P., Olsen, A., Wiggins, N., McDonald, D., & Fowle, C. (2015). Working together: Expanding the availability of naloxone for peer administration to prevent opioid overdose deaths in the Australian Capital Territory and beyond. *Drug Alcohol Rev*, 34(4), 404-411.

Lewis, C. R., Vo, H. T., & Fishman, M. (2017). Intranasal naloxone and related strategies for opioid overdose intervention by nonmedical personnel: a review. *Subst Abuse Rehabil*, 8, 79-95.

Lim, J. K., Forman, L. S., Ruiz, S., Xuan, Z., Callis, B. P., Cranston, K., & Walley, A. Y. (2019). Factors associated with help seeking by community responders trained in overdose prevention and naloxone administration in Massachusetts. *Drug Alcohol Depend*, 204, 107531.

Lintzeris, N., Monds, L. A., Bravo, M., Read, P., Harrod, M. E., Gilliver, R., . . . Malcom, A. (2020). Designing, implementing and evaluating the overdose response with take-home naloxone model of care: An evaluation of client outcomes and perspectives. *Drug Alcohol Rev*, 39(1), 55-65.

Lintzeris, N. (2020). Providing take home naloxone needs to be improved to prevent opioid overdose deaths. *Med J Aust*, 212(7), 307-308.

Lintzeris, N., Santo, T., Jr., Nielsen, S., Degenhardt, L., & Campbell, G. (2019). Estimating Centre for Disease Control and Prevention-defined overdose risk in people prescribed opioids for chronic non-cancer pain: implications for take-home naloxone provision. *Intern Med J*, 49(8), 1054-1055.

Liu, S., & Vivolo-Kantor, A. (2020). A latent class analysis of drug and substance use patterns among patients treated in emergency departments for suspected drug overdose. *Addict Behav*, 101, 106142.

Livingston, J. D., Milne, T., Fang, M. L., & Amari, E. (2012). The effectiveness of interventions for reducing stigma related to substance use disorders: a systematic review. *Addiction*, 107(1), 39-50.

Lockett, T. L., Hickman, K. L., Fils-Guerrier, B. J., Lomonaco, M., Maye, J. P., & Rossiter, A. G. (2018). Opioid Overdose and Naloxone Kit Distribution: A Quality Assurance Educational Program in the Primary Care Setting. *J Addict Nurs*, 29(3), 157-162.

- Loimer, N., Hofmann, P., & Chaudhry, H. R. (1992). Nasal administration of naloxone for detection of opiate dependence. *J Psychiatr Res*, *26*(1), 39-43.
- Lowenstein, M., Feuerstein-Simon, R., Dupuis, R., Herens, A., Hom, J., Sharma, M., . . . Cannuscio, C. (2020). Overdose Awareness and Reversal Trainings at Philadelphia Public Libraries. *Am J Health Promot*, 890117120937909.
- Lyden, J., & Binswanger, I. A. (2019). The United States opioid epidemic. *Semin Perinatol*, *43*(3), 123-131.
- Macleod, J., Steer, C., Tilling, K., Cornish, R., Marsden, J., Millar, T., . . . Hickman, M. (2019). Prescription of benzodiazepines, z-drugs, and gabapentinoids and mortality risk in people receiving opioid agonist treatment: Observational study based on the UK Clinical Practice Research Datalink and Office for National Statistics death records. *PLoS Med*, *16*(11), e1002965.
- Madah-Amiri, D., & Clausen, T. (2016). The use of public health infrastructure probably the best strategy for national and large-scale naloxone distribution programmes. *Addiction*, *111*(7), 1309-1310.
- Madah-Amiri, D., Clausen, T., & Lobmaier, P. (2016). Utilizing a train-the-trainer model for multi-site naloxone distribution programs. *Drug Alcohol Depend*, *163*, 153-156.
- Madah-Amiri, D., Clausen, T., & Lobmaier, P. (2017). Rapid widespread distribution of intranasal naloxone for overdose prevention. *Drug Alcohol Depend*, *173*, 17-23.
- Madah-Amiri, D., Clausen, T., Myrmed, L., Brattebo, G., & Lobmaier, P. (2017). Circumstances surrounding non-fatal opioid overdoses attended by ambulance services. *Drug Alcohol Rev*, *36*(3), 288-294.
- Madah-Amiri, D., Gjersing, L., & Clausen, T. (2018). Naloxone distribution and possession following a large-scale naloxone programme. *Addiction*.
- Madah-Amiri, D., Gjersing, L., & Clausen, T. (2019). Naloxone distribution and possession following a large-scale naloxone programme. *Addiction*, *114*(1), 92-100.
- Madah-Amiri, D., Skulberg, A. K., Braarud, A. C., Dale, O., Heyerdahl, F., Lobmaier, P., & Clausen, T. (2018). Ambulance-attended opioid overdoses: An examination into overdose locations and the role of a safe injection facility. *Subst Abuse*, 1-6.
- Madah-Amiri, D., Skulberg, A. K., Braarud, A. C., Dale, O., Heyerdahl, F., Lobmaier, P., & Clausen, T. (2019). Ambulance-attended opioid overdoses: An examination into overdose locations and the role of a safe injection facility. *Subst Abuse*, *40*(3), 383-388.
- Mahgoub, N., O'Connell, K., Gevint, K., Dedonatis, A., Velasco, J., Tham, A., . . . Anthony, D. (2020). An Inpatient Psychiatric Program Targeting Opioid Overdoses. *J Psychiatr Pract*, *26*(1), 71-75.
- Malta, M., Varatharajan, T., Russell, C., Pang, M., Bonato, S., & Fischer, B. (2019). Opioid-related treatment, interventions, and outcomes among incarcerated persons: A systematic review. *PLoS Med*, *16*(12), e1003002.
- Marteau, D., McDonald, R., & Patel, K. (2015). The relative risk of fatal poisoning by methadone or buprenorphine within the wider population of England and Wales. *BMJ Open*, *5*(5), e007629.
- Martins, S. S., Sampson, L., Cerda, M., & Galea, S. (2015). Worldwide Prevalence and Trends in Unintentional Drug Overdose: A Systematic Review of the Literature. *Am J Public Health*, *105*(11), e29-49.
- Matheson, C., Pflanz-Sinclair, C., Aucott, L., Wilson, P., Watson, R., Malloy, S., . . . McAuley, A. (2014). Reducing drug related deaths: a pre-implementation assessment of knowledge, barriers and enablers for naloxone distribution through general practice. *BMC Fam Pract*, *15*, 12.
- Maxwell, S., Bigg, D., Stanczykiewicz, K., & Carlberg-Racich, S. (2006). Prescribing naloxone to actively injecting heroin users: a program to reduce heroin overdose deaths. *J Addict Dis*, *25*(3), 89-96.
- Mayer, S., Boyd, J., Collins, A., Kennedy, M. C., Fairbairn, N., & McNeil, R. (2018). Characterizing fentanyl-related

overdoses and implications for overdose response: Findings from a rapid ethnographic study in Vancouver, Canada. *Drug Alcohol Depend*, 193, 69-74.

Mayet, S., Manning, V., Williams, A., Loaring, J., & Strang, J. (2011). Impact of training for healthcare professionals on how to manage an opioid overdose with naloxone: effective, but dissemination is challenging. *Int J Drug Policy*, 22(1), 9-15.

Mégarbane, B., Chevillard, L., & Vodovar, D. (2020). Naloxone should remain the appropriate antidote to treat opioid overdose. *Crit Care*, 24(1), 173

McAuley, A., Aucott, L., & Matheson, C. (2015). Exploring the life-saving potential of naloxone: A systematic review and descriptive meta-analysis of take home naloxone (THN) programmes for opioid users. *Int J Drug Policy*, 26(12), 1183-1188.

McAuley, A., Bouttell, J., Barnsdale, L., Mackay, D., Lewsey, J., Hunter, C., & Robinson, M. (2017). Evaluating the impact of a national naloxone programme on ambulance attendance at overdose incidents: a controlled time-series analysis. *Addiction*, 112(2), 301-308.

McAuley, A., Munro, A., Bird, S. M., Hutchinson, S. J., Goldberg, D. J., & Taylor, A. (2016). Engagement in a National Naloxone Programme among people who inject drugs. *Drug Alcohol Depend*, 162, 236-240.

McAuley, A., Munro, A., & Taylor, A. (2018). "Once I'd done it once it was like writing your name": Lived experience of take-home naloxone administration by people who inject drugs. *Int J Drug Policy*, 58, 46-54.

McCambridge, J., Gossop, M., Beswick, T., Best, D., Bearn, J., Rees, S., & Strang, J. (2007). In-patient detoxification procedures, treatment retention, and post-treatment opiate use: comparison of lofexidine + naloxone, lofexidine + placebo, and methadone. *Drug Alcohol Depend*, 88(1), 91-95.

McDonald, R., Campbell, N. D., & Strang, J. (2017). Twenty years of take-home naloxone for the prevention of overdose deaths from heroin and other opioids-Conception and maturation. *Drug Alcohol Depend*, 178, 176-187.

McDonald, R., Danielsson Glende, O., Dale, O., & Strang, J. (2018). International patent applications for non-injectable naloxone for opioid overdose reversal: Exploratory search and retrieve analysis of the PatentScope database. *Drug Alcohol Rev*, 37(2), 205-215.

McDonald, R., Lorch, U., Woodward, J., Bosse, B., Dooner, H., Mundin, G., . . . Strang, J. (2018). Pharmacokinetics of concentrated naloxone nasal spray for opioid overdose reversal: Phase I healthy volunteer study. *Addiction*, 113(3), 484-493.

McDonald, R., & Strang, J. (2016). Are take-home naloxone programmes effective? Systematic review utilizing application of the Bradford Hill criteria. *Addiction*, 111(7), 1177-1187.

McKnight, C., & Des Jarlais, D. C. (2018). Being "hooked up" during a sharp increase in the availability of illicitly manufactured fentanyl: Adaptations of drug using practices among people who use drugs (PWUD) in New York City. *Int J Drug Policy*, 60, 82-88.

Meade, A. M., Bird, S. M., Strang, J., Pepple, T., Nichols, L. L., Mascarenhas, M., . . . Parmar, M. K. B. (2018). Methods for delivering the UK's multi-centre prison-based naloxone-on-release pilot randomised trial (N-ALIVE): Europe's largest prison-based randomised controlled trial. *Drug Alcohol Rev*, 37(4), 487-498.

Mégarbane, B., Gouda, A. S., & El-Nabarawy, N. A. (2019). Understanding the risk of seizure in tramadol overdose: still a long way to go. *Clin Toxicol (Phila)*, 57(12), 1161-1162.

Merlin, M. A., Saybolt, M., Kapitanyan, R., Alter, S. M., Jeges, J., Liu, J., . . . Pryor, P. W., 2nd. (2010). Intranasal naloxone delivery is an alternative to intravenous naloxone for opioid overdoses. *Am J Emerg Med*, 28(3), 296-303.

Mitchell, K., Durante, S. E., Pellatt, K., Richardson, C. G., Mathias, S., & Buxton, J. A. (2017). Naloxone and the Inner City Youth Experience (NICYE): a community-based participatory research study examining young people's

perceptions of the BC take home naloxone program. *Harm Reduct J*, 14(1), 34.

Moe, J., Godwin, J., Pursell, R., O'Sullivan, F., Hau, J. P., Pursell, E., . . . Hohl, C. M. (2020). Naloxone dosing in the era of ultra-potent opioid overdoses: a systematic review. *Cjem*, 22(2), 178-186.

Montano, A. L. (2016). Naloxone Administration. *Am J Nurs*, 116(9), 13.

Moore, C., Lloyd, G., Oretti, R., Russell, I., & Snooks, H. (2014). Paramedic-supplied 'Take Home' Naloxone: protocol for cluster randomised feasibility study. *BMJ Open*, 4(3), e004712.

Moradmand-Badie, B., Tran, L., Oikarainen, N., Degenhardt, L., Nielsen, S., Roberts, J., . . . Larney, S. (2020). Feasibility and acceptability of take-home naloxone for people released from prison in New South Wales, Australia. *Drug Alcohol Rev*

Morris, H., Hagen, L., Hyshka, E., & Francescutti, L. H. (2019). Empowering Students and Influencing Policy Change Through Experiential Public Health Advocacy Education. *J Nurs Educ*, 58(12), 698-703.

Moustaqim-Barrette, A., Papamihali, K., Crabtree, A., Graham, B., Karamouzian, M., & Buxton, J. A. (2019). Correlates of take-home naloxone kit possession among people who use drugs in British Columbia: A cross-sectional analysis. *Drug Alcohol Depend*, 205, 107609.

Mullennix, S. C., Iseler, J., Kwiatkowski, G. M., McCann-Spry, L., Skinner, J., Kuhl, N., . . . Poland, C. A. (2020). A Clinical Nurse Specialist-Led Emergency Department Naloxone Distribution Program. *Clin Nurse Spec*, 34(3), 116-123.

Mueller, S. R., Walley, A. Y., Calcaterra, S. L., Glanz, J. M., & Binswanger, I. A. (2015). A Review of Opioid Overdose Prevention and Naloxone Prescribing: Implications for Translating Community Programming Into Clinical Practice. *Subst Abus*, 36(2), 240-253.

Mueller, S. R., Walley, A. Y., Calcaterra, S. L., Glanz, J. M., & Binswanger, I. A. (2015). A Review of Opioid Overdose Prevention and Naloxone Prescribing: Implications for Translating Community Programming Into Clinical Practice. *Subst Abus*, 36(2), 240-253.

Mueller, S.R., Koester, S., Glanz, J.M., Gardner, E.M., Binswanger, I.A., 2017. Attitudes toward naloxone prescribing in clinical settings: a qualitative study of patients prescribed high dose opioids for chronic non-cancer pain. *J. Gen. Intern. Med.* 32 (3), 312.

Mundin, G., McDonald, R., Smith, K., Harris, S., & Strang, J. (2017). Pharmacokinetics of concentrated naloxone nasal spray over first 30 minutes post-dosing: analysis of suitability for opioid overdose reversal. *Addiction*, 112(9), 1647-1652.

Murray, B. P., Carpenter, J. E., Dunkley, C. A., Moran, T. P., Alfaifi, M., Alsukaiti, W. S., & Kazzi, Z. (2019). Seizures in tramadol overdoses reported in the ToxIC registry: predisposing factors and the role of naloxone. *Clin Toxicol (Phila)*, 57(8), 692-696.

Naumann, R. B., Durrance, C. P., Ranapurwala, S. I., Austin, A. E., Proescholdbell, S., Childs, R., . . . Shanahan, M. E. (2019). Impact of a community-based naloxone distribution program on opioid overdose death rates. *Drug Alcohol Depend*, 204, 107536.

Neale, J., Bradford, J., & Strang, J. (2017). Development of a proto-typology of opiate overdose onset. *Addiction*, 112(1), 168-175.

Neale, J., Brown, C., Campbell, A. N. C., Jones, J. D., Metz, V. E., Strang, J., & Comer, S. D. (2019). How competent are people who use opioids at responding to overdoses? Qualitative analyses of actions and decisions taken during overdose emergencies. *Addiction*, 114(4), 708-718.

Neale, J., Kalk, N. J., Parkin, S., Brown, C., Brandt, L., Campbell, A. N. C., . . . Comer, S. D. (2020). Factors associated with withdrawal symptoms and anger among people resuscitated from an opioid overdose by take-home naloxone: Exploratory mixed methods analysis. *J Subst Abuse Treat*, 117, 108099.

- Neale, J., & Strang, J. (2015). Naloxone--does over-antagonism matter? Evidence of iatrogenic harm after emergency treatment of heroin/opioid overdose. *Addiction*, *110*(10), 1644-1652.
- Nielsen, S., Menon, N., Larney, S., Farrell, M., & Degenhardt, L. (2016). Community pharmacist knowledge, attitudes and confidence regarding naloxone for overdose reversal. *Addiction*, *111*(12), 2177-2186.
- Nielsen, S., Peacock, A., Lintzeris, N., Bruno, R., Larance, B., & Degenhardt, L. (2018). Knowledge of Opioid Overdose and Attitudes to Supply of Take-Home Naloxone Among People with Chronic Noncancer Pain Prescribed Opioids. *Pain Med*, *19*(3), 533-540.
- Notta, D., Black, B., Chu, T., Joe, R., & Lysyshyn, M. (2019). Changing risk and presentation of overdose associated with consumption of street drugs at a supervised injection site in Vancouver, Canada. *Drug Alcohol Depend*, *196*, 46-50.
- O'Brien, D. C., Dabbs, D., Dong, K., Veugelers, P. J., & Hyshka, E. (2019). Patient characteristics associated with being offered take home naloxone in a busy, urban emergency department: a retrospective chart review. *BMC Health Serv Res*, *19*(1), 632.
- Olsen, A., Dwyer, R., & Lenton, S. (2018). Take-home naloxone in Australia and beyond. *Drug Alcohol Rev*, *37*(4), 437-439.
- Palamar, J. J., Salomone, A., Bigiarini, R., Vincenti, M., Acosta, P., & Tofighi, B. (2019). Testing hair for fentanyl exposure: a method to inform harm reduction behavior among individuals who use heroin. *Am J Drug Alcohol Abuse*, *45*(1), 90-96.
- Papp, J., Vallabhaneni, M., Morales, A., & Schrock, J. W. (2019). Take -home naloxone rescue kits following heroin overdose in the emergency department to prevent opioid overdose related repeat emergency department visits, hospitalization and death- a pilot study. *BMC Health Serv Res*, *19*(1), 957.
- Parkin, S., Neale, J., Brown, C., Campbell, A. N. C., Castillo, F., Jones, J. D., . . . Comer, S. D. (2020). Opioid overdose reversals using naloxone in New York City by people who use opioids: Implications for public health and overdose harm reduction approaches from a qualitative study. *Int J Drug Policy*, *79*, 102751.
- Parmar, M. K., Strang, J., Choo, L., Meade, A. M., & Bird, S. M. (2017). Randomized controlled pilot trial of naloxone-on-release to prevent post-prison opioid overdose deaths. *Addiction*, *112*(3), 502-515.
- Paulozzi, L., Dellinger, A., & Degutis, L. (2012). Lessons from the past. *Inj Prev*, *18*(1), 70.
- Pearce, L. A., Min, J. E., Piske, M., Zhou, H., Homayra, F., Slaunwhite, A., . . . Nosyk, B. (2020). Opioid agonist treatment and risk of mortality during opioid overdose public health emergency: population based retrospective cohort study. *Bmj*, *368*, m772.
- Perri, M., & Strike, C. (2020). The missing link: Incorporating behaviour change theories in overdose education and naloxone distribution programs. *Int J Drug Policy*, *83*, 102853.
- Petterson, A. G., & Madah-Amiri, D. (2017). Overdose prevention training with naloxone distribution in a prison in Oslo, Norway: a preliminary study. *Harm Reduct J*, *14*(1), 74.
- Pierce, M., Millar, T., Robertson, J. R., & Bird, S. M. (2018). Ageing opioid users' increased risk of methadone-specific death in the UK. *Int J Drug Policy*, *55*, 121-127.
- Pietrusza, L. M., Puskar, K. R., Ren, D., & Mitchell, A. M. (2018). Evaluation of an Opiate Overdose Educational Intervention and Naloxone Prescribing Program in Homeless Adults Who Use Opiates. *J Addict Nurs*, *29*(3), 188-195.
- Piper, T. M., Rudenstine, S., Stancliff, S., Sherman, S., Nandi, V., Clear, A., & Galea, S. (2007). Overdose prevention for injection drug users: lessons learned from naloxone training and distribution programs in New York City. *Harm Reduct J*, *4*, 3.
- Pizzicato, L. N., Johnson, C. C., & Viner, K. M. (2020). Correlates of experiencing and witnessing non-fatal opioid

overdoses among individuals accessing harm reduction services in Philadelphia, Pennsylvania. *Subst Abus*, 41(3), 301-306.

Pearce, L. A., Min, J. E., Piske, M., Zhou, H., Homayra, F., Slaunwhite, A., . . . Nosyk, B. (2020). Opioid agonist treatment and risk of mortality during opioid overdose public health emergency: population based retrospective cohort study. *Bmj*, 368, m772.

Purssell, R., Godwin, J., Moe, J., Buxton, J., Crabtree, A., Kestler, A., . . . Brubacher, J. R. (2020). Comparison of rates of opioid withdrawal symptoms and reversal of opioid toxicity in patients treated with two naloxone dosing regimens: a retrospective cohort study. *Clin Toxicol (Phila)*, 1-9.

Priest, K. C., Gorfinkel, L., Klimas, J., Jones, A. A., Fairbairn, N., & McCarty, D. (2019). Comparing Canadian and United States opioid agonist therapy policies. *Int J Drug Policy*, 74, 257-265.

Ramos, A., Sarmiento, L., Dietz, N., Cordero, N., Levy, X., & Hennekens, C. H. (2020). Opioid overdoses: Emerging clinical challenges. *J Opioid Manag*, 16(2), 151-154.

Rando, J., Broering, D., Olson, J. E., Marco, C., & Evans, S. B. (2015). Intranasal naloxone administration by police first responders is associated with decreased opioid overdose deaths. *Am J Emerg Med*, 33(9), 1201-1204.

Rajesh, R., & Dasarathy, J. (2019). Would you be able to recognize the signs and symptoms of this particular drug overdose? *J Fam Pract*, 68(5), 290-292.

Ray, B., O'Donnell, D., & Kahre, K. (2015). Police officer attitudes towards intranasal naloxone training. *Drug Alcohol Depend*, 146, 107-110.

Ray, B. R., Lowder, E. M., Kivisto, A. J., Phalen, P., & Gil, H. (2018). EMS naloxone administration as non-fatal opioid overdose surveillance: 6-year outcomes in Marion County, Indiana. *Addiction*, 113(12), 2271-2279.

Reed, M., Wagner, K. D., Tran, N. K., Brady, K. A., Shinefeld, J., & Roth, A. (2019). Prevalence and correlates of carrying naloxone among a community-based sample of opioid-using people who inject drugs. *Int J Drug Policy*, 73, 32-35.

Reynolds, K. (2020). Opioid Overdose Prevention. *Am J Nurs*, 120(2), 10.

Richert, T. (2015). Wasted, overdosed, or beyond saving--to act or not to act? Heroin users' views, assessments, and responses to witnessed overdoses in Malmo, Sweden. *Int J Drug Policy*, 26(1), 92-99.

Robertson, T. M., Hendey, G. W., Stroh, G., & Shalit, M. (2009). Intranasal naloxone is a viable alternative to intravenous naloxone for prehospital narcotic overdose. *Prehosp Emerg Care*, 13(4), 512-515.

Robinson, A., & Wermeling, D. P. (2014). Intranasal naloxone administration for treatment of opioid overdose. *Am J Health Syst Pharm*, 71(24), 2129-2135.

Rowe, C., Santos, G. M., Vittinghoff, E., Wheeler, E., Davidson, P., & Coffin, P. O. (2015). Predictors of participant engagement and naloxone utilization in a community-based naloxone distribution program. *Addiction*, 110(8), 1301-1310.

Roxburgh, A., Hall, W. D., Gisev, N., & Degenhardt, L. (2019). Characteristics and circumstances of heroin and pharmaceutical opioid overdose deaths: Comparison across opioids. *Drug Alcohol Depend*, 205, 107533.

Roxburgh, A., Darke, S., Salmon, A. M., Dobbins, T., & Jauncey, M. (2017). Frequency and severity of non-fatal opioid overdoses among clients attending the Sydney Medically Supervised Injecting Centre. *Drug Alcohol Depend*, 176, 126-132.

Russolillo, A., Moniruzzaman, A., & Somers, J. M. (2018). Methadone maintenance treatment and mortality in people with criminal convictions: A population-based retrospective cohort study from Canada. *PLoS Med*, 15(7), e1002625.

Ryan, S. A., & Dunne, R. B. (2018). Pharmacokinetic properties of intranasal and injectable formulations of naloxone for community use: a systematic review. *Pain Manag*, 8(3), 231-245.

- Saini, R., Rao, R., Parmar, A., Mishra, A. K., Ambekar, A., Agrawal, A., & Dhingra, N. (2020). Rates, knowledge and risk factors of non-fatal opioid overdose among people who inject drugs in India: A community-based study. *Drug Alcohol Rev*, 39(1), 93-97.
- Samuels, E. A., Bernstein, S. L., Marshall, B. D. L., Krieger, M., Baird, J., & Mello, M. J. (2018). Peer navigation and take-home naloxone for opioid overdose emergency department patients: Preliminary patient outcomes. *J Subst Abuse Treat*, 94, 29-34.
- Samuels, E. A., Bernstein, S. L., Marshall, B. D. L., Krieger, M., Baird, J., & Mello, M. J. (2019). Corrigendum to "Peer navigation and take-home naloxone for opioid overdose emergency department patients: Preliminary patient outcomes" [J. Subst. Abuse. Treat. 94 (2018 Nov) 29-34]. *J Subst Abuse Treat*, 99, 8.
- Salvador, J. G., Sussman, A. L., Takeda, M. Y., Katzman, W. G., Moya Balasch, M., & Katzman, J. G. (2020). Barriers to and recommendations for take-home naloxone distribution: perspectives from opioid treatment programs in New Mexico. *Harm Reduct J*, 17(1), 31.
- Seal, K. H., Downing, M., Kral, A. H., Singleton-Banks, S., Hammond, J. P., Lorvick, J., . . . Edlin, B. R. (2003). Attitudes about prescribing take-home naloxone to injection drug users for the management of heroin overdose: a survey of street-recruited injectors in the San Francisco Bay Area. *J Urban Health*, 80(2), 291-301.
- Shakeri, S. H. R., Hassanian-Moghaddam, H., & Zamani, N. (2020). Safety of Naloxone in Opioid-Naïve Methadone Intoxicated Patients; a Case Series Study. *Arch Acad Emerg Med*, 8(1), e16.
- Shaw, L. V., Moe, J., Purssell, R., Buxton, J. A., Godwin, J., Doyle-Waters, M. M., . . . Hohl, C. M. (2019). Naloxone interventions in opioid overdoses: a systematic review protocol. *Syst Rev*, 8(1), 138.
- Sherman, S. G., Gann, D. S., Tobin, K. E., Latkin, C. A., Welsh, C., & Bielensohn, P. (2009). "The life they save may be mine": diffusion of overdose prevention information from a city sponsored programme. *Int J Drug Policy*, 20(2), 137-142.
- Shin, T. (2019). Prescription Drug and Alcohol Use Disorders: Safe Prescribing of Opioids. *FP Essent*, 478, 11-18.
- Skoy, E., Eukel, H., Werremeyer, A., Strand, M., Frenzel, O., & Steig, J. (2020). Implementation of a statewide program within community pharmacies to prevent opioid misuse and accidental overdose. *J Am Pharm Assoc (2003)*, 60(1), 117-121.
- Skulberg, A. K., Tylleskar, I., Nilsen, T., Skarra, S., Salvesen, O., Sand, T., . . . Dale, O. (2018). Pharmacokinetics and -dynamics of intramuscular and intranasal naloxone: an explorative study in healthy volunteers. *Eur J Clin Pharmacol*, 74(7), 873-883.
- Skulberg, A. K., Åsberg, A., Khiabani, H. Z., Røstad, H., Tylleskar, I., & Dale, O. (2019). Pharmacokinetics of a novel, approved, 1.4-mg intranasal naloxone formulation for reversal of opioid overdose—a randomized controlled trial. *Addiction*, 114(5), 859-867.
- Smith, J. O., Malinowski, S. S., & Ballou, J. M. (2019). Public perceptions of naloxone use in the outpatient setting. *Ment Health Clin*, 9(4), 275-279.
- Sondhi, A., Ryan, G., & Day, E. (2016). Stakeholder perceptions and operational barriers in the training and distribution of take-home naloxone within prisons in England. *Harm Reduct J*, 13, 5.
- Southwell, M., Shelly, S., MacDonald, V., Verster, A., & Maher, L. (2019). Transforming lives and empowering communities: evidence, harm reduction and a holistic approach to people who use drugs. *Curr Opin HIV AIDS*, 14(5), 409-414.
- Sordo, L., Barrio, G., Bravo, M. J., Indave, B. I., Degenhardt, L., Wiessing, L., . . . Pastor-Barriuso, R. (2017). Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. *BMJ*, 357, j1550.
- Sporer, K. A., Firestone, J., & Isaacs, S. M. (1996). Out-of-hospital treatment of opioid overdoses in an urban setting.

Acad Emerg Med, 3(7), 660-667.

Sporer, K. A. (2003). Strategies for preventing heroin overdose. *Bmj*, 326(7386), 442-444.

Strang, J. (2015). Death matters: understanding heroin/opiate overdose risk and testing potential to prevent deaths. *Addiction*, 110 Suppl 2, 27-35.

Strang, J., Best, D., Man, L., Noble, A., & Gossop, M. (2000). Peer-initiated overdose resuscitation: fellow drug users could be mobilised to implement resuscitation. *Int J Drug Policy*, 11(6), 437-445.

Strang, J., Bird, S. M., Dietze, P., Gerra, G., & McLellan, A. T. (2014). Take-home emergency naloxone to prevent deaths from heroin overdose. *BMJ*, 349, g6580.

Strang, J., Bird, S. M., & Parmar, M. K. (2013). Take-home emergency naloxone to prevent heroin overdose deaths after prison release: rationale and practicalities for the N-ALIVE randomized trial. *J Urban Health*, 90(5), 983-996.

Strang, J., Darke, S., Hall, W., Farrell, M., & Ali, R. (1996). Heroin overdose: the case for take-home naloxone. *BMJ*, 312(7044), 1435-1436.

Strang, J., Kelleher, M., Best, D., Mayet, S., & Manning, V. (2006). Emergency naloxone for heroin overdose. *BMJ*, 333(7569), 614-615.

Strang, J., Manning, V., Mayet, S., Best, D., Titherington, E., Santana, L., . . . Semmler, C. (2008). Overdose training and take-home naloxone for opiate users: prospective cohort study of impact on knowledge and attitudes and subsequent management of overdoses. *Addiction*, 103(10), 1648-1657.

Strang, J., & McDonald, R. (2016). Letters to *Addiction* from Coffin et al. and Doe-Simpkins et al. re: 'For Debate' on clinical use of improvised nasal naloxone sprays: authors' response. *Addiction*, 111(10), 1881-1883.

Strang, J., & McDonald, R. (2016). New approved nasal naloxone welcome, but unlicensed improvised naloxone spray kits remain a concern: proper scientific study must accompany innovation. *Addiction*, 111(4), 590-592.

Strang, J., McDonald, R., Alqurshi, A., Royall, P., Taylor, D., & Forbes, B. (2016). Naloxone without the needle - systematic review of candidate routes for non-injectable naloxone for opioid overdose reversal. *Drug Alcohol Depend*, 163, 16-23.

Strang, J., McDonald, R., Alqurshi, A., Royall, P., Taylor, D., & Forbes, B. (2016). Naloxone without the needle - systematic review of candidate routes for non-injectable naloxone for opioid overdose reversal. *Drug Alcohol Depend*, 163, 16-23.

Strang, J., McDonald, R., Campbell, G., Degenhardt, L., Nielsen, S., Ritter, A., & Dale, O. (2019). Take-Home Naloxone for the Emergency Interim Management of Opioid Overdose: The Public Health Application of an Emergency Medicine. *Drugs*, 79(13), 1395-1418.

Strang, J., McDonald, R., Tas, B., & Day, E. (2016). Clinical provision of improvised nasal naloxone without experimental testing and without regulatory approval: imaginative shortcut or dangerous bypass of essential safety procedures? *Addiction*, 111(4), 574-582.

Strang, J., Neale, J., McDonald, R., & Kalk, N. (2018). Toxicity: exploring and expanding the concept. *Addiction*, 113(4), 592-594.

Strang, J., Powis, B., Best, D., Vingoe, L., Griffiths, P., Taylor, C., . . . Gossop, M. (1999). Preventing opiate overdose fatalities with take-home naloxone: pre-launch study of possible impact and acceptability. *Addiction*, 94(2), 199-204.

Strang, J., Volkow, N. D., Degenhardt, L., Hickman, M., Johnson, K., Koob, G. F., . . . Walsh, S. L. (2020). Opioid use disorder. *Nat Rev Dis Primers*, 6(1), 3.

Strike, C., & Watson, T. M. (2019). Losing the uphill battle? Emergent harm reduction interventions and barriers

during the opioid overdose crisis in Canada. *Int J Drug Policy*, 71, 178-182.

Teesson, M., Marel, C., Darke, S., Ross, J., Slade, T., Burns, L., . . . Mills, K. L. (2017). Trajectories of heroin use: 10-11-year findings from the Australian Treatment Outcome Study. *Addiction*, 112(6), 1056-1068

Tas, B., Humphreys, K., McDonald, R., & Strang, J. (2019). Should we worry that take-home naloxone availability may increase opioid use? *Addiction*, 114(10), 1723-1725.

Tas, B., & McDonald, R. (2016). Commentary on Darke & Dufrou (2016): Heroin-related deaths-identifying a window for intervention. *Addiction*, 111(9), 1614-1615.

Thylstrup, B., Hesse, M., Jørgensen, M., & Thiesen, H. (2019). One opioid user saving another: the first study of an opioid overdose-reversal and naloxone distribution program addressing hard-to-reach drug scenes in Denmark. *Harm Reduct J*, 16(1), 66.

Tobin, K., Clyde, C., Davey-Rothwell, M., & Latkin, C. (2018). Awareness and access to naloxone necessary but not sufficient: Examining gaps in the naloxone cascade. *Int J Drug Policy*, 59, 94-97.

Tormohlen, K. N., Tobin, K. E., Davey-Rothwell, M. A., & Latkin, C. (2019). Low overdose responding self-efficacy among adults who report lifetime opioid use. *Drug Alcohol Depend*, 201, 142-146.

Traynor, K. (2016). FDA approves first intranasal naloxone product. *Am J Health Syst Pharm*, 73(1), e2-3.

Townsend, T., Blostein, F., Doan, T., Madson-Olson, S., Galecki, P., & Hutton, D. W. (2020). Cost-effectiveness analysis of alternative naloxone distribution strategies: First responder and lay distribution in the United States. *Int J Drug Policy*, 75, 102536

Tran, L. T., Peacock, A., Colledge, S., Memedovic, S., Grebely, J., Leung, J., . . . Degenhardt, L. (2020). Injecting risk behaviours amongst people who inject drugs: A global multi-stage systematic review and meta-analysis. *Int J Drug Policy*, 84, 102866.

Troberg, K., Isendahl, P., Blome, M. A., Dahlman, D., & Hakansson, A. (2020). Protocol for a multi-site study of the effects of overdose prevention education with naloxone distribution program in Skane County, Sweden. *BMC Psychiatry*, 20(1), 49.

Tylleskar, I., Skulberg, A. K., Nilsen, T., Skarra, S., & Dale, O. (2019). Naloxone nasal spray - bioavailability and absorption pattern in a phase 1 study. *Tidsskr Nor Laegeforen*, 139(13).

Uyei, J., Fiellin, D. A., Buchelli, M., Rodriguez-Santana, R., & Braithwaite, R. S. (2017). Effects of naloxone distribution alone or in combination with addiction treatment with or without pre-exposure prophylaxis for HIV prevention in people who inject drugs: a cost-effectiveness modelling study. *Lancet Public Health*, 2(3), e133-e140.

Volkow, N. D., Jones, E. B., Einstein, E. B., & Wargo, E. M. (2019). Prevention and Treatment of Opioid Misuse and Addiction: A Review. *JAMA Psychiatry*, 76(2), 208-216.

Waddell, E. N., Baker, R., Hartung, D. M., Hildebran, C. J., Nguyen, T., Collins, D. M., . . . Stack, E. (2020). Reducing overdose after release from incarceration (ROAR): study protocol for an intervention to reduce risk of fatal and non-fatal opioid overdose among women after release from prison. *Health Justice*, 8(1), 18.

Wagner, K. D., Davidson, P. J., Iverson, E., Washburn, R., Burke, E., Kral, A. H., . . . Lankenau, S. E. (2014). "I felt like a superhero": The experience of responding to drug overdose among individuals trained in overdose prevention. *International Journal of Drug Policy*, 25, 157-165.

Wagner, K. D., Harding, R. W., Kelley, R., Labus, B., Verdugo, S. R., Copulsky, E., . . . Davidson, P. J. (2019). Post-overdose interventions triggered by calling 911: Centering the perspectives of people who use drugs (PWUDs). *PLoS One*, 14(10), e0223823.

Wagner, K. D., Iverson, E., Wong, C. F., Bloom, J. J., McNeeley, M., Davidson, P. J., . . . Lankenau, S. E. (2013). Personal social network factors associated with overdose prevention training participation. *Subst Use Misuse*,

48(1-2), 21-30.

Wagner, K. D., Valente, T. W., Casanova, M., Partovi, S. M., Mendenhall, B. M., Hundley, J. H., . . . Unger, J. B. (2010). Evaluation of an overdose prevention and response training programme for injection drug users in the Skid Row area of Los Angeles, CA. *Int J Drug Policy, 21*(3), 186-193.

Walley, A. Y., Xuan, Z., Hackman, H. H., Quinn, E., Doe-Simkins, M., Sorensen-Alawad, A., . . . Ozonoff, A. (2013). Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: interrupted time series analysis. *BMJ, 346*, f174

Walsh, S. L., Nuzzo, P. A., Babalonis, S., Casselton, V., & Lofwall, M. R. (2016). Intranasal buprenorphine alone and in combination with naloxone: Abuse liability and reinforcing efficacy in physically dependent opioid abusers. *Drug Alcohol Depend, 162*, 190-198.

Warner-Smith, M., Darke, S., Linskey, M., & Hall, W. (2001). Heroin overdose: causes and consequences. *Addiction, 96*, 1113–1125.

Waskel, E. N., Antonio, S. C., Irio, G., Campbell, J. L., & Kramer, J. (2020). The impact of medical school education on the opioid overdose crisis with concurrent training in naloxone administration and MAT. *J Addict Dis, 38*(3), 380-383.

Waye, K. M., Goyer, J., Dettor, D., Mahoney, L., Samuels, E. A., Yedinak, J. L., & Marshall, B. D. L. (2019). Implementing peer recovery services for overdose prevention in Rhode Island: An examination of two outreach-based approaches. *Addict Behav, 89*, 85-91.

Weiner Sg, M. M., Baker O, P., Bernson D, M. P. H., & Schuur Jd, M. M. (2020). One year mortality of patients treated with naloxone for opioid overdose by emergency medical services. *Subst Abus, 1*-5.

Welch, A. E., Jeffers, A., Allen, B., Paone, D., & Kunins, H. V. (2019). Relay: A Peer-Delivered Emergency Department-Based Response to Nonfatal Opioid Overdose. *Am J Public Health, 109*(10), 1392-1395.

Wenger, L. D., Showalter, D., Lambdin, B., Leiva, D., Wheeler, E., Davidson, P. J., . . . Kral, A. H. (2019). Overdose Education and Naloxone Distribution in the San Francisco County Jail. *J Correct Health Care, 25*(4), 394-404.

Weiner, S. G., Baker, O., Bernson, D., & Schuur, J. D. (2020). One-Year Mortality of Patients After Emergency Department Treatment for Nonfatal Opioid Overdose. *Ann Emerg Med, 75*(1), 13-17.

Wermeling, D. P. (2010). Opioid harm reduction strategies: focus on expanded access to intranasal naloxone. *Pharmacotherapy, 30*(7), 627-631.

Wheeler, E., Jones, T. S., Gilbert, M. K., & Davidson, P. J. (2015). Opioid Overdose Prevention Programs Providing Naloxone to Laypersons - United States, 2014. *MMWR Morb Mortal Wkly Rep, 64*(23), 631-635.

Wilson, N., Kariisa, M., Seth, P., Smith, H. t., & Davis, N. L. (2020). Drug and Opioid-Involved Overdose Deaths - United States, 2017-2018. *MMWR Morb Mortal Wkly Rep, 69*(11), 290-297.

Williams, A. V., Marsden, J., & Strang, J. (2014). Training family members to manage heroin overdose and administer naloxone: randomized trial of effects on knowledge and attitudes. *Addiction, 109*(2), 250-259.

Williams, A. V., Strang, J., & Marsden, J. (2013). Development of Opioid Overdose Knowledge (OOKS) and Attitudes (OOAS) Scales for take-home naloxone training evaluation. *Drug Alcohol Depend, 132*(1-2), 383-386.

Winstanley, E. L., Clark, A., Feinberg, J., & Wilder, C. M. (2016). Barriers to implementation of opioid overdose prevention programs in Ohio. *Subst Abus, 37*(1), 42-46.

Wilson, J. D., Berk, J., Adger, H., & Feldman, L. (2018). Identifying Missed Clinical Opportunities in Delivery of Overdose Prevention and Naloxone Prescription to Adolescents Using Opioids. *J Adolesc Health, 63*(2), 245-248.

Winston, I., McDonald, R., Tas, B., & Strang, J. (2015). Heroin overdose resuscitation with naloxone: patient uses own prescribed supply to save the life of a peer. *BMJ Case Rep, 2015*.

Winter, R. J., Stoové, M., Degenhardt, L., Hellard, M. E., Spelman, T., Jenkinson, R., . . . Kinner, S. A. (2015). Incidence and predictors of non-fatal drug overdose after release from prison among people who inject drugs in Queensland, Australia. *Drug Alcohol Depend*, 153, 43-49.

Visconti, A. J., Sell, J., & Greenblatt, A. D. (2019). Primary Care for Persons Who Inject Drugs. *Am Fam Physician*, 99(2), 109-116.

Wolfson-Stofko, B., Gwadz, M. V., Elliott, L., Bennett, A. S., & Curtis, R. (2018). "Feeling confident and equipped": Evaluating the acceptability and efficacy of an overdose response and naloxone administration intervention to service industry employees in New York City. *Drug Alcohol Depend*, 192, 362-370.

Yedinak, J. L., Goedel, W. C., Paull, K., Lebeau, R., Krieger, M. S., Thompson, C., . . . Marshall, B. D. L. (2019). Defining a recovery-oriented cascade of care for opioid use disorder: A community-driven, statewide cross-sectional assessment. *PLoS Med*, 16(11), e1002963

Young, S., Williams, S., Otterstatter, M., Lee, J., & Buxton, J. (2019). Lessons learned from ramping up a Canadian Take Home Naloxone programme during a public health emergency: a mixed-methods study. *BMJ Open*, 9(10), e030046.

Yousefifard, M., Vazirizadeh-Mahabadi, M. H., Neishaboori, A. M., Alavi, S. N. R., Amiri, M., Baratloo, A., & Saberian, P. (2020). Intranasal versus Intramuscular/Intravenous Naloxone for Pre-hospital Opioid Overdose: A Systematic Review and Meta-analysis. *Adv J Emerg Med*, 4(2), e27.

Stigma (föredrag 2019)

Behar, E., et al. (2019). "Perceived Causes of Personal versus Witnessed Overdoses among People who Inject Opioids." *Subst Use Misuse*: 1-9.

Bennett, A. S., et al. (2019). "Commentary on Madah-Amiri et al. (2019): Beyond saturation." *Addiction* 114(1): 101-102

Black, L., et al. (2017). "Poor implementation of naloxone needs to be better understood in order to save lives." *Addiction* 112(5): 911-912.

Coffin, P. O., et al. (2016). "Nonrandomized Intervention Study of Naloxone Coprescription for Primary Care Patients Receiving Long-Term Opioid Therapy for Pain." *Ann Intern Med* 165(4): 245-252.

Dechman, M. K. (2015). Peer helpers' struggles to care for "others" who inject drugs. *Int J Drug Policy*, 26(5), 492-500. doi:10.1016/j.drugpo.2014.12.010

Farrugia, A., et al. (2019). "Take-home naloxone and the politics of care." *Sociol Health Illn* 41(2): 427-443.

Faulkner-Gurstein, R. (2017). "The social logic of naloxone: Peer administration, harm reduction, and the transformation of social policy." *Soc Sci Med* 180: 20-27.

Gaston, R. L., et al. (2009). "Can we prevent drug related deaths by training opioid users to recognise and manage overdoses?" *Harm Reduct J* 6: 26.

Gowan, T., Whetstone, S., & Andic, T. (2012). Addiction, agency, and the politics of self-control: doing harm reduction in a heroin users' group. *Soc Sci Med*, 74(8), 1251-1260. doi:10.1016/j.socscimed.2011.11.045

Heavey, S. C., et al. (2018). "'I have it just in case' - Naloxone access and changes in opioid use behaviours." *Int J Drug Policy* 51: 27-35.

Holland, T. J., et al. (2019). "Emergency department physicians' and pharmacists' perspectives on take-home naloxone." *Drug Alcohol Rev* 38(2): 169-176.

Latkin, C. A., et al. (2019). "Stigma and drug use settings as correlates of self-reported, non-fatal overdose among people who use drugs in Baltimore, Maryland." *Int J Drug Policy* 68: 86-92.